ArticlePloS one2013
Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Modulation of cecal microbiota and metabolite profiles by Zanthoxylum bungeanum seeds enhances antioxidant capacity and meat quality in Pekin ducks.Poultry science · 2026Article
- A comparative framework of natural nisin variants: linking genetic basis to future bioengineering applications.Microbial cell factories · 2026Review
- Alternative approaches to antibiotics in the control of mastitis in dairy cows: a review.Veterinary research communications · 2025Review
- In Bacterial Membranes Lipid II Changes the Stability of Pores Formed by the Antimicrobial Peptide Nisin.The journal of physical chemistry. B · 2024Article
- Rombocin, a Short Stable Natural Nisin Variant, Displays Selective Antimicrobial Activity againstACS synthetic biology · 2024Article
- Cesin, a short natural variant of nisin, displays potent antimicrobial activity against major pathogens despite lacking two C-terminal macrocycles.Microbiology spectrum · 2023Article
- Engineering of Nisin as a Means for Improvement of Its Pharmacological Properties: A Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- After a century of nisin research - where are we now?FEMS microbiology reviews · 2023Review
- Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Nisin Variants Generated by Protein Engineering and Their Properties.Bioengineering (Basel, Switzerland) · 2022Review
- Bio-Engineered Nisin with Increased Anti-International journal of molecular sciences · 2021Article
- Recipe for Success: Suggestions and Recommendations for the Isolation and Characterisation of Bacteriocins.International journal of microbiology · 2021Review
- Bioengineered Nisin Derivative M17Q Has Enhanced Activity againstAntibiotics (Basel, Switzerland) · 2020Article
- Multispecies activity screening of microcin J25 mutants yields antimicrobials with increased specificity toward pathogenic Salmonella species relative to human commensal Escherichia coli.Biotechnology and bioengineering · 2018Article
- High-resolution NMR studies of antibiotics in cellular membranes.Nature communications · 2018Article
- The potency of the broad spectrum bacteriocin, bactofencin A, against staphylococci is highly dependent on primary structure, N-terminal charge and disulphide formation.Scientific reports · 2018Article
- Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids.Journal of visualized experiments : JoVE · 2018Article
- Expanding the Genetic Code ofFrontiers in microbiology · 2018Article
- Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Chemical reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is becoming increasingly apparent that innovations from the "golden age" of antibiotics are becoming ineffective, resulting in a pressing need for novel therapeutics. The bacteriocin family of antimicrobial peptides has attracted much attention in recent years as a source of potential alternatives. The most intensively studied bacteriocin is nisin, a broad spectrum lantibiotic that inhibits gram-positive bacteria including important food pathogens and clinically relevant antibiotic resistant bacteria. Nisin is gene-encoded and, as such, is amenable to peptide bioengineering, facilitating the generation of novel derivatives that can be screened for desirable properties. It was to this end that we used a site-saturation mutagenesis approach to create a bank of producers of nisin A derivatives that differ with respect to the identity of residue 12 (normally lysine; K12). A number of these producers exhibited enhanced bioactivity and the nisin A K12A producer was deemed of greatest interest. Subsequent investigations with the purified antimicrobial highlighted the enhanced specific activity of this modified nisin against representative target strains from the genera Streptococcus, Bacillus, Lactococcus, Enterococcus and Staphylococcus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.